Combination with F8-IL2, a tumor-targeted version of human IL2, did result in substantially improved therapeutic effect, which was, however, not superior to F8-IL2 monotherapy, suggesting that IL2 preferentially acted on the preexisting immune infiltrate, rather than on injected T cells. The gene discussed is IL2; the disease is neoplasm.